US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.88

+0.63001.69%

Post-market: 37.880.00000.00%19:30 EDT

Volume:52.02K

Turnover:1.97M

Market Cap:342.44M

PE:- -

High:37.97

Open:37.82

Low:37.60

Close:37.25

52wk High:39.80

52wk Low:30.66

Shares:9.04M

Float Shares:9.04M

Volume Ratio:0.80

T/O Rate:0.58%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cellectis Reports Financial Results for the First Quarter 2026

Alpha Tau Completes Patient Enrollment for U.S. Clinical Trial of Novel Radiotherapy

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Immunocore reports first quarter financial results and provides a business update

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Immutep Quarterly Activities Report Q3 FY26

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Accent Trial Mature Data Presented at International Conference

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

Benzinga_recent_news

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

World's First CAR-T Therapy for Solid Tumors Available in China Soon

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/ORR/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.88,"timestamp":1790971200000,"preClose":37.25,"halted":0,"volume":52018,"hourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016912751677852417,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"Market Closed","change":0.63,"latestTime":"10-02 16:00:00 EDT","open":37.82,"high":37.9699,"low":37.6,"amount":1965631.8915940002,"amplitude":0.00993,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":37.25,"sharesOutstanding":12900000,"nav":37.48,"aum":338819200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.798571665918667,"impliedVol":0.202,"impliedVolPercentile":0.7043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9040000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.798571665918667,"shares":9040000,"dividePrice":0,"high":37.9699,"amplitude":0.00993,"preClose":37.25,"low":37.6,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":37.88,"eps":0,"divideRate":0,"volume":52018,"delay":0,"ttmEps":0,"open":37.82,"prevYearClose":34.16,"prevWeekClose":38.3781,"prevMonthClose":37.77,"prevQuarterClose":37.77,"fiveDayClose":38.3781,"twentyDayClose":39.1754,"sixtyDayClose":36.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634230959","title":"Cellectis Reports Financial Results for the First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230959?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:30","pubTimestamp":1778531400,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3292381/0/en/Cellectis-Reports-Financial-Results-for-the-First-Quarter-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","CR","LU0963586101.USD","CLLS","BK4006","IE00B19Z4B17.USD","ORR","BK4187","LU2065731478.USD","BK4161","IE0031619046.USD","BK4139","IE00B7SZL793.SGD","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109158909","title":"Alpha Tau Completes Patient Enrollment for U.S. Clinical Trial of Novel Radiotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1109158909","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109158909?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:12","pubTimestamp":1778245934,"startTime":"0","endTime":"0","summary":"Israeli medical company Alpha Tau Medical Ltd. announced today that it has completed enrollment of all 88 patients for its U.S. multicenter pivotal clinical trial (ReSTART) evaluating the novel...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145122","title":"Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145122","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145122?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:00","pubTimestamp":1778245200,"startTime":"0","endTime":"0","summary":"- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3291075/0/en/Alpha-Tau-Completes-Patient-Enrollment-in-its-U-S-Pivotal-Skin-Cancer-Study-Advancing-Towards-Goal-of-FDA-Approval-of-Alpha-DaRT-to-Treat-Recurrent-Cutaneous-Squamous-Cell-Carcinom.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182528","title":"Immunocore reports first quarter financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182528","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633182528?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065200,"startTime":"0","endTime":"0","summary":"Immunocore reports first quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: K","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288641/0/en/Immunocore-reports-first-quarter-financial-results-and-provides-a-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CRS","BK4195","IE00B66KJ199.SGD","IE00BFXG0V08.USD","IND","MTD","LU0963586101.USD","ALT","BK4147","BK4548","LU2413666699.HKD","BK4121","IE00B5TLWC47.USD","LU1878469433.USD","BK4007","BK4599","ATOM","LU1093756168.USD","IE00B7SZL793.SGD","CM","LU1093756325.SGD","LU2413666426.HKD","LU0347712357.USD","IE0031619046.USD","BK4139","LU2211817866.USD","CTA","IE00BYQQ9H92.USD","BK4187","BK4207","BK4533","IE00B19Z4B17.USD","ORR","BK4588","PFS","BK4006","PROC","BK4567","LU2065731478.USD","LU1721428933.USD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633240359","title":"Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633240359","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633240359?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011500,"startTime":"0","endTime":"0","summary":"FDA Breakthrough Therapy designation granted tozovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doub","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288234/0/en/Relay-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IE00BHPRN162.USD","BK4139","PFS","WT","BK4195","BK4135","RLAY","TAT","BK4211","ORR","USA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633791044","title":"Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633791044","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633791044?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982400,"startTime":"0","endTime":"0","summary":"Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287628/0/en/Zentalis-Pharmaceuticals-Announces-First-Patient-Dosed-in-ASPENOVA-Phase-3-Trial-of-Azenosertib-in-Patients-with-Cyclin-E1-Positive-Platinum-Resistant-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4195","BK4211","PFS","PROC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633338917","title":"Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633338917","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633338917?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:30","pubTimestamp":1777980600,"startTime":"0","endTime":"0","summary":"paclitaxel alone as well as clear signals of a survival benefit in a. Phase 2/3 study of patients with biliary tract cancer ; tovecimig. previously met the primary endpoint of overall response rate .-- Tovecimig received Orphan Drug Designation in April and the Company. intends to meet with the FDA in advance of its planned BLA submission. -- The Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific. antibody) has been selected for a poster presentation at the American. three deep responses  in patients treated in the. post-checkpoint inhibitor setting; cohort expansions in these indications. -- The Phase 1 study for CTX-10726  has. \"In the post-checkpoint inhibitor setting where treatment alternatives are also critically needed, we have ongoing studies with very two promising candidates. Our novel PD-1 x PD-L1 checkpoint inhibitor CTX-8371 continues to demonstrate strong and durable clinical activity and we look forward to presenting dose-escalation and early expansion co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","PFS","BK4195","CMPX","BTC","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637961","title":"Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637961","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631637961?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:31","pubTimestamp":1777552260,"startTime":"0","endTime":"0","summary":"Ramat Gan, Israel, April  30, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284876/0/en/Can-Fite-Reports-Positive-Phase-2a-Data-with-Namodenoson-in-Pancreatic-Cancer-35-of-Patients-Remain-on-Therapy-Including-One-Beyond-16-Months.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4006","ORR","PFS","BK4181","HCC","BK4211","PK","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634961","title":"Immutep Quarterly Activities Report Q3 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634961","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634961?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550400,"startTime":"0","endTime":"0","summary":"Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284806/0/en/Immutep-Quarterly-Activities-Report-Q3-FY26.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4107","LU0210528500.USD","LU2487616109.SGD","IMMP","BK4139","BK4585","BK4588","LU0053666078.USD","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630525317","title":"Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2630525317","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630525317?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:01","pubTimestamp":1777320060,"startTime":"0","endTime":"0","summary":"Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281996/0/en/Erasca-Announces-Positive-Preliminary-Phase-1-Dose-Escalation-Data-for-Potentially-Best-in-Class-Pan-RAS-Molecular-Glue-ERAS-0015-in-KRAS-Mutant-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4539","PD","BK4023","DCO","LU0566484027.USD","BK4187","IE00B7SZL793.SGD","CRC","ERAS","BK4213","LU0456854461.SGD","PK","LU0266512127.USD","IE0031619046.USD","IE00B66KJ199.SGD","LU1169589451.USD","ADME","CN","ORR","BK4218","LU1559883803.SGD","BK4139","IE00B19Z4B17.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395644","title":"Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395644","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630395644?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:30","pubTimestamp":1777289400,"startTime":"0","endTime":"0","summary":"Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of medi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281512/0/en/Tovecimig-Demonstrates-Statistically-Significant-Benefit-in-COMPANION-002-Randomized-Phase-2-3-Study-in-Patients-with-Biliary-Tract-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTC","BK4211","PFS","BK4195","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629893041","title":"Accent Trial Mature Data Presented at International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2629893041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629893041?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:45","pubTimestamp":1776861900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Mature data from Amplia’s ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meetingThe ACCENT trial investigates ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278983/0/en/Accent-Trial-Mature-Data-Presented-at-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","INNMF","ORR","BK4139","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629877995","title":"Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629877995","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629877995?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:00","pubTimestamp":1776718800,"startTime":"0","endTime":"0","summary":"SHANGHAI, April  20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3277510/0/en/Junshi-Biosciences-Presents-Results-from-JS207-PD-1-VEGF-BsAb-Phase-2-Combo-Studies-and-JS212-EGFR-HER3-ADC-FIH-Phase-1-2-Study-at-AACR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","LU1093756168.USD","LU2211817866.USD","BK1508","HCC","BK4080","LU1169590202.USD","BK4213","ORR","IE00BFXG0V08.USD","BK1167","BK4585","PD","BK4023","IND","IE00BYQQ9H92.USD","PR","LU1721428933.USD","CDX","BK4195","MTD","BK1504","BK4211","IE00B5TLWC47.USD","BK4121","BK4231","BK4588","LU2413666699.HKD","ADC","LU0347712357.USD","BK4567","LU1093756325.SGD","02038","BK4533","LU2413666426.HKD","SD","LU1169589451.USD","BK4006","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627931287","title":"PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627931287","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627931287?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:45","pubTimestamp":1776257100,"startTime":"0","endTime":"0","summary":"78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Tria","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274455/37149/en/PDS-Biotech-Announces-Publication-of-Positive-PDS01ADC-Interim-Phase-2-Clinical-Trial-Data-from-Stage-1-of-NCI-led-Metastatic-Colorectal-Cancer-mCRC-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDS","BK4588","BK1550","BK4581","BK4231","LU0572940350.SGD","ORR","BK1184","BK1584","BK4585","LU0264606111.USD","PFS","BK4211","BK4080","ADC","BK4195","BK4113","LU0572939691.SGD","01336","MSS","BK4092","BK4202","XBI","NCI","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627555674","title":"Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2627555674","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627555674?lang=en_us&edition=fundamental","pubTime":"2026-04-13 21:00","pubTimestamp":1776085200,"startTime":"0","endTime":"0","summary":"The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate  of 99%. WOBURN, Mass., April 13, 2026 /PRNewswire/ --Sirtex Medical , a leading manufacturer of interventional oncology and embolization solutions, today announced landmark 12-month results from the DOORwaY90 study, the first pivotal, prospective, multicenter U.S. trial of Y-90 selective internal radiation therapy  using partition dosimetry in patients with unresectable hepatocellular carcinoma .The DOORwaY90 study met its prespecified co-primary endpoints, demonstrating a 90% complete response  rate and a best overall response rate  of 99%, as assessed by blinded independent central review. All evaluable patients responded to treatment, resulting in 100% local tumor control—one of the highest reported response outcomes in Y-90 therapy. Responses were durable, with 75% lasting beyond six months and a median duration of 295 days, reinforcing the potential of SIR-Spheres Y-90 resin micr","market":"hk","thumbnail":"https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sirtex-medicals-doorway90-study-demonstrates-100-local-tumor-control-with-sir-spheres-setting-a-new-benchmark-in-y-90-for-hcc-302739680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK7095","CR","ORR","SIR","BK4006","USA","ORR.AU","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627430977","title":"IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2627430977","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627430977?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:48","pubTimestamp":1776080880,"startTime":"0","endTime":"0","summary":"IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/13/Eye-In-Close-Up-With-Light-Blue-Iris-Det.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/13/Eye-In-Close-Up-With-Light-Blue-Iris-Det.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/04/51775855/ideaya-eye-cancer-trial-data-beats-standard-therapy-stock-soars","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4217","SMA","BK4195","BK4124","IDYA","SMP","BK4139","BK4150","PFS","BK4211","ORR","RSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215188","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215188","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215188?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:34","pubTimestamp":1775723640,"startTime":"0","endTime":"0","summary":"NANJING, China, April  09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270693/0/en/Leads-Biolabs-Opamtistomig-PD-L1-4-1BB-Bispecific-Antibody-Advances-to-Expansion-Phase-in-First-Line-Biliary-Tract-Cancer-Following-Positive-Safety-and-Preliminary-Efficacy-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF417.EUR","IE00B2PGVK34.USD","LU2023250504.SGD","LU2360108059.USD","LU2092937221.SGD","LU1169590202.USD","BTC","LU2023250843.SGD","BK4183","LU2298321311.HKD","LU2041044095.USD","LU2106854487.HKD","BK4006","HCC","BK4023","ORR","IE0009354923.USD","LU0868494617.USD","LU2048586759.USD","LU1974910355.USD","LU1917777945.USD","BK4086","PD","OC","ODD","IE00B3CCJ633.GBP","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626905589","title":"World's First CAR-T Therapy for Solid Tumors Available in China Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2626905589","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626905589?lang=en_us&edition=fundamental","pubTime":"2026-04-09 13:36","pubTimestamp":1775712960,"startTime":"0","endTime":"0","summary":"A New Hope for Patients with Advanced Gastric and Pancreatic Cancers. SHANGHAI, April 9, 2026 /PRNewswire/ -- A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients.The therapy, known as satri-cel , is the world's first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2, a biomarker commonly found in gastric  and pancreatic cancers.CAR-T therapy is a highly personalized treatment that uses a patient's own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time.While CAR-T has already transformed outcomes in blood cancers, this new therapy represen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/worlds-first-car-t-therapy-for-solid-tumors-available-in-china-soon-302737791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK7095","ORR","CAR","ORR.AU","BK4022"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":118,"code":"91000000","status":"200"}]}}